1. Cell Cycle/DNA Damage
  2. PPAR
  3. Ciprofibrate

Ciprofibrate (Synonyms: Win35833)

Cat. No.: HY-B0664 Purity: 99.79%
Handling Instructions

Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias.

For research use only. We do not sell to patients.

Ciprofibrate Chemical Structure

Ciprofibrate Chemical Structure

CAS No. : 52214-84-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 172 In-stock
Estimated Time of Arrival: December 31
100 mg USD 156 In-stock
Estimated Time of Arrival: December 31
500 mg USD 576 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Ciprofibrate:

Top Publications Citing Use of Products

View All PPAR Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha[1]. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias[2].

IC50 & Target[1]

PPARα

 

In Vitro

Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells[1].
In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid[2].
Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%[3].
Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents in HepG2 cells[3].
Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of  choline-deficient (MCD) diet-fed mice[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (six-week-old males)[3]
Dosage: 10 mg/kg
Administration: Oral administration; 10 mg/kg/day; 3 days
Result: Decreased MCD diet-resulted hepatic steatosis and hepatic necro-inflammation in mice.
Clinical Trial
Molecular Weight

289.15

Formula

C₁₃H₁₄Cl₂O₃

CAS No.

52214-84-3

SMILES

CC(C)(OC1=CC=C(C2C(Cl)(Cl)C2)C=C1)C(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (345.84 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4584 mL 17.2921 mL 34.5841 mL
5 mM 0.6917 mL 3.4584 mL 6.9168 mL
10 mM 0.3458 mL 1.7292 mL 3.4584 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

CiprofibrateWin35833Win 35833Win-35833PPARPeroxisome proliferator-activated receptorsperoxisomeproliferatorhypolipidaemic hyperlipidaemias PPARalphaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ciprofibrate
Cat. No.:
HY-B0664
Quantity:
MCE Japan Authorized Agent: